2024
DOI: 10.1001/jamainternmed.2023.8029
|View full text |Cite
|
Sign up to set email alerts
|

Outcomes of Various Classes of Oral Antidiabetic Drugs on Nonalcoholic Fatty Liver Disease

Heejoon Jang,
Yeonjin Kim,
Dong Hyeon Lee
et al.

Abstract: ImportanceSeveral oral antidiabetic drug (OAD) classes can potentially improve patient outcomes in nonalcoholic fatty liver disease (NAFLD) to varying degrees, but clinical data on which class is favored are lacking.ObjectiveTo investigate which OAD is associated with the best patient outcomes in NAFLD and type 2 diabetes (T2D).Design, Setting, and ParticipantsThis retrospective nonrandomized interventional cohort study used the National Health Information Database, which provided population-level data for Kor… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 55 publications
(96 reference statements)
0
1
0
Order By: Relevance
“…Recent studies have demonstrated the usefulness of the diabetes mellitus drugs sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) for treatment of MASLD. Thus, their potential as therapeutic agents is expanding [ 10 - 12 ], and in actual clinical practice, there are many MASH/MASLD patients already taking SGLT-2i and GLP-1RA. In addition, the United States Food and Drug Administration recently approved the first oral thyroid hormone receptor-beta selective agonist [ 13 ] for MASH/MASLD treatment.…”
Section: What Is the Most Important Combination Of CM In Masld?mentioning
confidence: 99%
“…Recent studies have demonstrated the usefulness of the diabetes mellitus drugs sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) for treatment of MASLD. Thus, their potential as therapeutic agents is expanding [ 10 - 12 ], and in actual clinical practice, there are many MASH/MASLD patients already taking SGLT-2i and GLP-1RA. In addition, the United States Food and Drug Administration recently approved the first oral thyroid hormone receptor-beta selective agonist [ 13 ] for MASH/MASLD treatment.…”
Section: What Is the Most Important Combination Of CM In Masld?mentioning
confidence: 99%
“…As a result, although the use of metformin alone in treating subjects with liver steatosis is not convincingly supported, so far, a number of ongoing trials oriented to the management of the steatotic liver include the use of metformin together with other anti-diabetic drugs as SGLT-2 inhibitors, pioglitazone, liraglutide, gliclazide, sitagliptin [ 262 ]. In a recent Korean retrospective, nonrandomized interventional cohort study in patients with T2DM classified as NAFLD, SGLT2 inhibitors, thiazolidinediones, and DPP-4 inhibitors, each combined with metformin, have been associated with a clinical regression of NAFLD, when compared with the combination metformin- sulfonylureas [ 263 ].…”
Section: Therapeutic Management Of Masldmentioning
confidence: 99%